Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Operations: 2013-2024

Historic Cash from Operations for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$69.7 million.

  • Zevra Therapeutics' Cash from Operations rose 125.96% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year increase of 66.42%. This contributed to the annual value of -$69.7 million for FY2024, which is 107.74% down from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Cash from Operations is -$69.7 million, which was down 107.74% from -$33.5 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Cash from Operations ranged from a high of $10.4 million in FY2021 and a low of -$69.7 million during FY2024.
  • For the 3-year period, Zevra Therapeutics' Cash from Operations averaged around -$40.6 million, with its median value being -$33.5 million (2023).
  • As far as peak fluctuations go, Zevra Therapeutics' Cash from Operations skyrocketed by 638.37% in 2021, and later tumbled by 279.30% in 2022.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Cash from Operations stood at -$1.9 million in 2020, then skyrocketed by 638.37% to $10.4 million in 2021, then plummeted by 279.30% to -$18.7 million in 2022, then crashed by 79.17% to -$33.5 million in 2023, then plummeted by 107.74% to -$69.7 million in 2024.